Compare STIM & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STIM | STTK |
|---|---|---|
| Founded | 2003 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 105.5M | 119.0M |
| IPO Year | 2018 | 2020 |
| Metric | STIM | STTK |
|---|---|---|
| Price | $1.43 | $3.05 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $7.00 | $4.00 |
| AVG Volume (30 Days) | ★ 1.3M | 355.1K |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $129,873,000.00 | $1,000,000.00 |
| Revenue This Year | $101.67 | N/A |
| Revenue Next Year | $10.87 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 78.61 | N/A |
| 52 Week Low | $1.23 | $0.69 |
| 52 Week High | $5.92 | $3.38 |
| Indicator | STIM | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 40.71 | 67.21 |
| Support Level | $1.28 | $2.82 |
| Resistance Level | $1.79 | $3.30 |
| Average True Range (ATR) | 0.15 | 0.24 |
| MACD | 0.06 | -0.00 |
| Stochastic Oscillator | 28.57 | 74.76 |
Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulations, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.